References
- 1. Alba AC, Bain E, Ng N, Stein M, Brien KO. Complications after Heart Transplantation: Hope for the Best, but Prepare for the Worst. Int J Transplant Res Med. 2016;2(2):2:022. DOI: 10.23937/2572-4045.151002210.23937/2572-4045.1510022
- 2. Szymanska S, Grajkowska W, Sobieszczanska-Malek M, Zielinski T, Pyzlak M, Pronicki M. Prevalence of the Quilty effect in endomyocardial biopsy of patients after heart transplantation - from cellular rejection to antibody-mediated rejection? Pol J Pathol. 2016;67(3):216-20. DOI: 10.5114/pjp.2016.6377210.5114/pjp.2016.6377228155969
- 3. Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol. 2008;52(8):587-98. DOI: 10.1016/j.jacc.2008.05.02010.1016/j.jacc.2008.05.02018702960
- 4. Cipullo R, Finger MA, Rossi Neto JM, Contreras CM, Poltronieri NV, Zamorano Mde M, et al. Vasculitides and eosinophils in endomyocardial biopsies as rejection predictors in heart transplantation. Arq Bras Cardiol. 2011;97(2):163-70. DOI: 10.1590/S0066-782X201100500006910.1590/S0066-782X201100500006921655876
- 5. Mozaffari K, Bakhshandeh H, Amin A, Naderi N, Taghavi S, Ojaghi-Haghighi Z, et al. Diagnostic Pitfalls and Challenges in Interpretation of Heart Transplantation Rejection in Endomyocardial Biopsies With Focus on our Experience. Res Cardiovasc Med. 2014;3(1):e13986. DOI: 10.5812/cardiovascmed.1398610.5812/cardiovascmed.13986425374425478529
- 6. Zakliczynski M, Nozynski J, Konecka-Mrowka D, Pyka L, Trybunia D, Swierad M, et al. Quilty effect correlates with biopsy-proven acute cellular rejection but does not predict transplanted heart coronary artery vasculopathy. J Heart Lung Transplant. 2009;28(3):255-9. DOI: 10.1016/j.healun.2008.12.01110.1016/j.healun.2008.12.01119285617
- 7. Chu KE, Ho EK, de la Torre L, Vasilescu ER, Marboe CC. The relationship of nodular endocardial infiltrates (Quilty lesions) to survival, patient age, anti-HLA antibodies, and coronary artery disease following heart transplantation. Cardiovasc Pathol. 2005;14(4):219-24. DOI: 10.1016/j.carpath.2005.03.00910.1016/j.carpath.2005.03.00916009321
- 8. Rigol M, Solanes N, Sionis A, Galvez C, Martorell J, Rojo I, et al. Effects of cyclosporine, tacrolimus and sirolimus on vascular changes related to immune response. J Heart Lung Transplant. 2008;27(4):416-22. DOI: 10.1016/j.healun.2008.01.00610.1016/j.healun.2008.01.00618374878
- 9. Joong A, Richmond ME, Stack KO, Rodriguez RJ, McAllister JM, Zuckerman WA, et al. The Quilty Effect in Pediatric Heart Transplant Recipients. The Journal of Heart and Lung Transplantation. 35(4):S75. DOI: 10.1016/j.healun.2016.01.20410.1016/j.healun.2016.01.204
- 10. Cho H, Choi JO, Jeon ES, Kim JS. Quilty Lesions in the Endomyocardial Biopsies after Heart Transplantation. J Pathol Transl Med. 2019;53(1):50-6. DOI: 10.4132/jptm.2018.11.3010.4132/jptm.2018.11.30634480130586951
- 11. Marboe CC, Billingham M, Eisen H, Deng MC, Baron H, Mehra M, et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant. 2005;24(7 Suppl):S219-26. DOI: 10.1016/j.healun.2005.04.00110.1016/j.healun.2005.04.001
- 12. Kobashigawa J, Wener L, Johnson J, Currier JW, Yeatman L, Cassem J, et al. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. J Heart Lung Transplant. 2000;19(6):546-50. DOI: 10.1016/S1053-2498(00)00100-510.1016/S1053-2498(00)00100-5
- 13. Minicucci MF, Zornoff LAM. VEGFR-2: One of Pioglitazone’s Signaling Pathways in the Heart. Arq Bras Cardiol. 2018;111(2):170-1. DOI: 10.5935/abc.2018014710.5935/abc.20180147
- 14. Waltenberger J, Kranz A, Beyer M. Neovascularization in the human heart is associated with expression of VEGF-A and its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2). Results from cardiomyopexy in ischemic cardiomyopathy. Angiogenesis. 1999;3(4):345-51. DOI: 10.1023/A:102658590039810.1023/A:1026585900398
- 15. Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ. Cardiac allograft vasculopathy: a review. Can J Surg. 2005;48(4):319-27.
- 16. Patel JK, Kobashigawa JA. Cardiac transplant experience with cyclosporine. Transplant Proc. 2004;36(2 Suppl):323S-30S. DOI: 10.1016/j.transproceed.2004.01.03910.1016/j.transproceed.2004.01.039
- 17. Maravić-Stojković V, Stojković B, Perić M. Modern immunosuppressive agents after heart transplantation. Curr Trend Cardiol. 2017;1(2):41-8.
- 18. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6(6):1377-86. DOI: 10.1111/j.1600-6143.2006.01290.x10.1111/j.1600-6143.2006.01290.x
- 19. Lopez Garcia-Gallo C, Garcia Fadul C, Laporta R, Portero F, Millan I, Ussetti P. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience. Ann Transplant. 2015;20:661-6. DOI: 10.12659/AOT.89469410.12659/AOT.894694
- 20. Luckraz H, Charman SC, Wreghitt T, Wallwork J, Parameshwar J, Large SR. Does cytomegalovirus status influence acute and chronic rejection in heart transplantation during the ganciclovir prophylaxis era? J Heart Lung Transplant. 2003;22(9):1023-7. DOI: 10.1016/S1053-2498(02)01185-310.1016/S1053-2498(02)01185-3
- 21. Bolovan-Fritts CA, Trout RN, Spector SA. High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage. Blood. 2007;110(6):1857-63. DOI: 10.1182/blood-2007-03-07888110.1182/blood-2007-03-078881197635717519388
- 22. Frantzeskaki FG, Karampi ES, Kottaridi C, Alepaki M, Routsi C, Tzanela M, et al. Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers. J Crit Care. 2015;30(2):276-81. DOI: 10.1016/j.jcrc.2014.10.00210.1016/j.jcrc.2014.10.00225457114
- 23. Liu XF, Wang X, Yan S, Zhang Z, Abecassis M, Hummel M. Epigenetic control of cytomegalovirus latency and reactivation. Viruses. 2013;5(5):1325-45. DOI: 10.3390/v505132510.3390/v5051325371231023698401
- 24. Barge-Caballero E, Almenar-Bonet L, Crespo-Leiro MG, Brossa-Loidi V, Rangel-Sousa D, Gomez-Bueno M, et al. Preoperative Toxoplasma gondii serostatus does not affect long-term survival of cardiac transplant recipients. Analysis of the Spanish Heart Transplantation Registry. Int J Cardiol. 2018;250:183-7. DOI: 10.1016/j.ijcard.2017.09.21510.1016/j.ijcard.2017.09.21529031991
- 25. Kittleson MM, Kobashigawa JA. Toxoplasma gondii exposure in the heart transplant recipient: good, bad, or indifferent? Transplantation. 2013;96(12):1025. DOI: 10.1097/TP.0b013e3182a9276910.1097/TP.0b013e3182a9276924092388
- 26. Vitrone M, Iossa D, Rinaldi L, Pafundi PC, Molaro R, Parrella A, et al. Hepatitis B virus reactivation after heart transplant: Incidence and clinical impact. J Clin Virol. 2017;96:54-9. DOI: 10.1016/j.jcv.2017.09.01110.1016/j.jcv.2017.09.01128964958
- 27. Iossa D, Vitrone M, Liotti A, Portella G, Durante-Mangoni E, Zampino R. Hepatitis B core-related antigen to detect hepatitis B virus (HBV) reactivation in heart transplant recipients with past HBV infection: A pilot study. Clin Transplant. 2019;33(6):e13574. DOI: 10.1111/ctr.1357410.1111/ctr.1357431013373